Search Results

ECG is intended to disclose either normal condition or patterns of arrhythmia, myocardial ischemia, rate abnormalities, or features of prognostic value in the following cases: Patients with suspected cardiac abnormalities Populations of patients at an age or period in which a routine baseline evaluation of ECG characteristics is desired. Stress Testing Angina pectoris (chest pain) is a clinical syndrome resulting from myocardial ischemia, indicative of reduced blood supply to the cardiac muscle. The electrocardiogram may establish the diagnosis of ischemic heart disease if characteristic changes are present. Stress testing is the most widely used method to decide whether this chest pain is related to myocardial ischemia, and thus to coronary artery disease. In stress testing, the contractile capability of the heart muscle is monitored via ECG during patient exercise. Patients exercise by bioycle, treadmill, or other means, while the ECG is monitored continuously. Exercise body of treading, on one may of The ECG signals as well as the HF-QRS signals are recorded for the resting, exercise, andreasonals phase portions of the exercise protocol. The changes in both ECG waveforms are compared to the resting ECG records. In the HyperQ™ stress test, changes in the high frequency of the mid QRS complex, calculated as root-mean-square (RMS) values, are compared to the resting values. Most of the commercial stress test systems control the bicycle or treadmill automatically according to the requirements of the chosen protocol, although this is not essential. ST segment monitoring is intended as an aid in the evaluation of myocardial ischemia in patients with known or suspected coronary artery disease. The ST segment algorithm has been tested for accuracy of the ST segment data, and a database is used as a tool for performance testing. The significance of the ST segment changes must be determined by a physician. HyperQ™ The HyperQ™ Software is intended to be used as an aid to the ECG stress test by means of analysis of high frequency components present within the central portion of the QRS complex. The significance of the HF-QRS changes must be determined by a physician.

The HyperQ™ AD-100 System is a compact monitor for measuring, processing, storing, and displaying information derived from an electrocardiogram (ECG). The device analyzes and records the high frequency components of the QRS complex of standard ECG.

Here's an analysis of the provided text regarding the acceptance criteria and study for the HyperQ™ AD-100 System, structured to address your specific points.

Important Note: The provided document is a 510(k) Summary of Safety & Effectiveness for a medical device. This type of document is a summary and often refers to detailed reports (e.g., validation results) not included in the summary itself. Therefore, some specific details you requested (like exact sample sizes for test/training, number/qualifications of experts, or specific effect sizes from MRMC studies) are often not explicitly stated in a 510(k) summary, as these are typically found in the full submission. I will extract what is explicitly available and note where information is not provided.

Acceptance Criteria and Device Performance Study for HyperQ™ AD-100 System

Based on the provided K102579 510(k) Summary, the device is largely presented as "substantially equivalent" to a predicate device (HyperQ™ System K082564). The primary difference is the ability to be an accessory. The summary states that "Based upon the validation results, BSP believes this change does not raise additional safety or efficacy concerns." This indicates that the new device is expected to perform at least as well as the predicate and that the validation study aimed to confirm this.

1. Table of Acceptance Criteria and Reported Device Performance

The document does not explicitly state quantitative acceptance criteria or a specific table for "reported device performance" in the way one might expect for a new diagnostic accuracy claim (e.g., sensitivity, specificity thresholds). Instead, the performance is generally framed around its "substantial equivalence" to the predicate device and the continuation of its intended use.

The closest we get to performance criteria are the technical specifications, which are identical to the predicate device, implying that meeting these specifications is a form of acceptance criterion to maintain equivalence. The "performance" is then demonstrating that the modified device still adheres to these specifications and intended uses, particularly regarding the HyperQ™ analysis and ST segment monitoring.

The core "acceptance criterion" for this 510(k) appears to be demonstrating that the new device, despite being an accessory and having slight physical differences, performs the intended functions (ECG, stress testing, HyperQ analysis, ST segment monitoring) to the same standard as the predicate device, especially regarding safety and efficacy.

2. Sample Size Used for the Test Set and Data Provenance

• Sample Size for Test Set: The document explicitly states "a database is used as a tool for performance testing" for the ST segment algorithm and refers to "validation results" for the device as a whole. However, the specific sample size (number of patients/cases) used for these test sets is not provided in this summary.
• Data Provenance: Not explicitly stated (e.g., country of origin, retrospective/prospective). The manufacturer is based in Israel, so it's possible the data originated there, but this is not confirmed.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications

• Number of Experts: Not specified.
• Qualifications of Experts: Not specified.

4. Adjudication Method for the Test Set

• Adjudication Method: Not specified.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

• MRMC Study Done?: Not explicitly mentioned. The focus is on the device's technical specifications and maintaining its intended functions, rather than a direct comparison of human readers with and without AI assistance. The HyperQ™ Software is "intended to be used as an aid," implying human-in-the-loop, but no study comparing human performance with and without this specific AI aid is described here.
• Effect Size of Human Reader Improvement: Not applicable, as no MRMC study details are provided.

6. Standalone (Algorithm Only) Performance Study

• Standalone Study Done?: Yes, to an extent. The document states, "The ST segment algorithm has been tested for accuracy of the ST segment data, and a database is used as a tool for performance testing." This implies an evaluation of the algorithm's output (ST segment data) against a reference, which is a standalone assessment. Similarly, the statement "In the HyperQ™ stress test, changes in the high frequency of the mid QRS complex, calculated as root, mean-square (RMS) values, are compared to the resting values" describes an algorithmic function. The summary itself does not provide quantitative results (e.g., sensitivity, specificity) of this standalone performance.

7. Type of Ground Truth Used

• Ground Truth Type:
  • For ST segment algorithm accuracy: "a database is used as a tool for performance testing." While not explicitly stated, clinical consensus from expert cardiologists or reference ECG analyses would be the most common ground truth for such assessments.
  • For HyperQ™ analysis: The ground truth is implicit in the comparison "changes in the high frequency of the mid QRS complex...are compared to the resting values." This suggests a comparative approach to a baseline, rather than an external "ground truth" for the HyperQ™ values themselves. The significance of these changes, however, "must be determined by a physician," implying that the ultimate clinical ground truth relies on expert interpretation in context.

8. Sample Size for the Training Set

• Sample Size for Training Set: Not provided. The summary mentions "a database" for testing, but doesn't elaborate on specific training data. Given the context of a 510(k) for an accessory that builds on an existing predicate, there might have been a development database for the original HyperQ™ system, but details for the AD-100's specific training are not in this summary.

9. How the Ground Truth for the Training Set Was Established

• Ground Truth for Training Set: Not provided. (See point 8).

In summary, this 510(k) document primarily asserts substantial equivalence based on technical specifications and the continued intended use of the device's analytical capabilities (HyperQ™ and ST segment monitoring). While it states that "validation results" confirm that changes do not raise new safety or efficacy concerns and that the ST segment algorithm has been "tested for accuracy," it does not provide granular details on the methodologies (sample sizes, expert qualifications, specific performance metrics, ground truth establishment) of these validation studies as would typically be found in a full scientific publication or the more extensive 510(k) submission itself.

Ask a specific question about this device